Serena Mandla

Company: Noa Therapeutics

Job title: Cso

Bio:

Serena Mandla, P.Eng., MASc., is the Chief Scientific Officer & Co-Founder of Noa Therapeutics, preclinical biotech company based in JLABS pioneering the development of novel biased small molecule therapeutics to reestablish innate immune equilibrium for diseases such as atopic dermatitis and IBD/ulcerative colitis. At Noa Therapeutics, Serena leads the Research and Development team and their efforts to advance their first product into the clinic, while expanding their drug discovery efforts to identify novel small molecule compounds.
Prior to Noa Therapeutics, Serena was involved in a spin-out from her MASc in Biomedical Engineering from the University of Toronto, Quthero Inc., where Serena has successfully raised financing and commercialized products for accelerating skin repair. She has over 15 scientific papers, from her research at the University of Toronto, and Harvard and is passionate about translating research and bringing it to the clinic and is looking forward to seeing and developing new technologies and treatments.

Seminars:

Panel Discussion: Can Topical and Systemic Therapies Each Find Their Place in the Future of Dermatology Drug Development? 3:30 pm

How should we balance the clinical and commercial drivers behind topical and systemic innovation, especially as realworld prescribing habits continue to favor topicals? How are these approaches viewed from the patient, regulator and investor perspective? Which factors, including disease severity, body surface area, and treatment setting, best guide whether a topical, systemic, or combination approach…Read more

day: Day One PM